MDM2 inhibitors (Hudson Biopharma)

N/A

Report date: 2026/03/30 17:02:26

Base Information

Drug NameMDM2 inhibitors (Hudson Biopharma)
Drug Alias Namespiroindolinone derivative (Hudson Biopharma)luobigewan
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of Actionp53-binding protein Mdm-2 inhibitors
Targetsp53-binding protein Mdm-2
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesHudson Biopharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesHudson Biopharma Inc
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A